62nd ASH Annual Meeting and Exposition: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I

Oral and Poster Abstracts
Poster

ALL, antibodies, apoptosis, Biological, Follicular Lymphoma, Leukemia, multiple myeloma, cell division, CLL, Diseases, Lymphoma (any), Marginal Zone Lymphoma, Non-Biological, CAR-Ts, cell regulation, Combinations, Mantle Cell Lymphoma, Therapies, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DLBCL, DNA damage, enzyme inhibitors, DNA repair, T-Cell Lymphoma, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, pharmacology, inflammation, pathogenesis, pathways, signal transduction

1173

A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

Jie Wang, MD, MS¹, Katarzyna Urbanska, PhD²^*, Prannda Sharma³^*, Mathilde Poussin³^*, Reza Nejati, MD⁴^*, Lauren Shaw³^*, Megan S. Lim, MD, PhD⁵, Stephen J. Schuster, MD⁵ and Daniel Powell Jr., PhD⁶^*

¹Duke University, Durham, NC
²Bristol-Meyers Squibb, Philadelphia, PA
³University of Pennsylvania, Philadelphia, PA
⁴Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA
⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁶Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA

1174

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Elana Thieme, BS¹^*, Vi Lam¹^*, Nur Bruss, BS¹^*, Fei Xu¹^*, Stephen E Kurtz, PhD²^*, Jeffrey W. Tyner, PhD³, Alexey Danilov, MD⁴ and Tingting Liu¹^*

¹Oregon Health and Science University, Portland, OR
²Knight Cancer Institute, Mail code: KR-HEM, Oregon Health & Science University, Portland, OR
³Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
⁴Knight Cancer Institute, Oregon Health & Science University, Portland, OR

1175

Identification of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

Wu Yin, PhD¹, Nie Zhe, PhD²^*, Andrew Placzek, PhD¹^*, Michael Trzoss, PhD³^*, Goran Krilov, PhD¹^*, Shulu Feng, PhD⁴^*, Morgan Lawrenz, PhD⁵^*, Robert Pelletier, PhD³^*, George Lai, PhD⁶^*, Jeff Bell, PhD³^*, David Calkins³^*, Mary Grimes³^*, Wayne Tang, PhD³^*, Fiona McRobb, PhD⁵^*, Aleksey Gerasyuto, PhD⁵^*, Victoria Feher, PhD³^*, Sayan Mondal, PhD⁴^*, Kristian Jensen, PhD³^*, Hamish Wright, PhD³^* and Karen Akinsanya, PhD⁴^*

¹Schrodinger, New York, NY
²Schrodinger, New York, NJ
³Schrodinger, New York
⁴schrodinger, New york
⁵Schrodinger, New york
⁶Triplet Therapeutics, Boston

1176

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Juan J Gu, MD, PhD^1,2^*, Cory Mavis, MSc^1,2^*, Pallawi Torka, MD¹^*, Suchitra Sundaram, MD¹^* and Francisco J. Hernandez-Ilizaliturri, MD^2,3

¹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
²Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
³Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

1177

STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias

Andy Parker, PhD

Step Pharma, Paris, France, France

1178

Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models

Asma Jabeen, PhD¹^*, Shiran Huang²^*, John A. Hartley, PhD²^*, Patrick H Van Berkel, PhD¹^* and Francesca Zammarchi, PhD¹^*

¹ADC Therapeutics (UK) Limited, London, ENG, United Kingdom
²UCL Cancer Institute, London, United Kingdom

1179

In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice

Eliana B. Gomez, PhD¹^*, Wenjuan Wu, PhD²^*, Jennifer R Stephens, BS²^*, Mary S. Rosendahl, PhD¹^* and Barbara J. Brandhuber, PhD¹^*

¹Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Boulder, CO
²Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN

1180

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Tingting Liu¹^*, Fei Xu²^*, Elana Thieme, BS¹^*, Vi Lam³^*, Guang Fan, MD, PhD⁴, Liana Nikolaenko, MD⁵, Stephen E Kurtz, PhD⁶^*, Jeffrey W. Tyner, PhD⁷, Olga Danilova¹^* and Alexey Danilov, MD⁸

¹City of Hope, Duarte, CA
²Oregon Health and Science University, Portland, OR
³City Of Hope, Duarte, CA
⁴Department of Pathology, Oregon Health and Science University, Portland, OR
⁵Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
⁶Knight Cancer Institute, Mail code: KR-HEM, Oregon Health & Science University, Portland, OR
⁷Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
⁸Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

1181

Abemaciclib-Based Combinational Therapies to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Yuxuan Che¹^*, Yang Liu, PhD¹^*, Lingzhi Li¹^*, Holly Hill¹^*, Joseph McIntosh, BS¹^*, Alexa A Jordan, BS¹^*, Dayoung Jung¹^*, Yixin Yao, PhD¹, Vivian Changying Jiang, PhD¹ and Michael Wang, MD^1,2

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

625.P1.27 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I